In the male breast cancer cohort, the different HER2 statuses were categorised as HER2-null, HER2-ultralow, HER2-low and HER2-positive, but there was no statistically significant difference between the four groups in terms of DFS and OS. The gene discussed is ERBB2; the disease is breast carcinoma.